Fulcrum Therapeutics, Inc. (FULC) Revenue History
Annual and quarterly revenue from 2017 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
FULC Revenue Growth
FULC Revenue Analysis (2017–2025)
As of May 8, 2026, Fulcrum Therapeutics, Inc. (FULC) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue.
Looking at the longer-term picture, FULC's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $80.0 million in 2024.
When compared to Healthcare sector peers including ARWR (+14.1% YoY), SRPT (-2.2% YoY), and FOLD (+20.0% YoY). Compare FULC vs ARWR →
FULC Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| FULCCurrent | $0 | - | - | - | |
 ARWR | $829M | +14.1% | +56.6% | 11.9% | |
 SRPT | $2.2B | -2.2% | +32.4% | -29.9% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 CRSP | $4M | -88.9% | +37.3% | -16191.4% |
FULC Historical Revenue Data (2017–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | -100.0% | $-1,390,000 | - | $-84,769,000 | - |
| 2024 | $80.0M | +2752.0% | $16.6M | 20.8% | $-21,897,000 | -27.4% |
| 2023 | $2.8M | -55.8% | $2.8M | 100.0% | $-110,664,000 | -3945.2% |
| 2022 | $6.3M | -66.9% | $-70,440,000 | -1110.7% | $-112,561,000 | -1774.9% |
| 2021 | $19.2M | +117.2% | $-50,538,000 | -263.7% | $-81,054,000 | -423.0% |
| 2020 | $8.8M | - | $-50,219,000 | -569.2% | $-71,611,000 | -811.6% |
| 2019 | $0 | - | $-2,053,000 | - | $-58,626,000 | - |
| 2018 | $0 | - | $-1,345,000 | - | $-33,498,000 | - |
| 2017 | $0 | - | $-715,000 | - | $-22,993,000 | - |
See FULC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs FULC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare FULC vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonFULC — Frequently Asked Questions
Quick answers to the most common questions about buying FULC stock.
Is FULC's revenue growth accelerating or slowing?
FULC TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is FULC's long-term revenue growth rate?
Fulcrum Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is FULC's revenue distributed by segment?
FULC reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2025 are available for download. Segment mix reveals concentration and diversification trends.